stoxline Quote Chart Rank Option Currency Glossary
  
VolitionRx Limited (VNRX)
0.6926  -0.047 (-6.41%)    06-12 15:59
Open: 0.7294
High: 0.736
Volume: 87,591
  
Pre. Close: 0.74
Low: 0.6926
Market Cap: 57(M)
Technical analysis
2024-06-12 4:25:52 PM
Short term     
Mid term     
Targets 6-month :  0.94 1-year :  1.05
Resists First :  0.8 Second :  0.89
Pivot price 0.7
Supports First :  0.66 Second :  0.54
MAs MA(5) :  0.69 MA(20) :  0.72
MA(100) :  0.86 MA(250) :  0.95
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  36.5 D(3) :  27.2
RSI RSI(14): 45.7
52-week High :  1.78 Low :  0.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VNRX ] has closed above bottom band by 35.7%. Bollinger Bands are 60.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.74 - 0.74 0.74 - 0.74
Low: 0.68 - 0.69 0.69 - 0.69
Close: 0.68 - 0.69 0.69 - 0.7
Company Description

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Headline News

Wed, 05 Jun 2024
VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - MarketBeat

Tue, 28 May 2024
VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com - MarketBeat

Tue, 14 May 2024
VolitionRx Limited (VNRX) Q1 2024 Earnings Call Transcript - Seeking Alpha

Mon, 08 Apr 2024
VNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key ... - Zacks Small Cap Research

Wed, 27 Mar 2024
VolitionRx Limited (AMEX:VNRX) Q4 2023 Earnings Call Transcript - Yahoo Finance

Mon, 25 Mar 2024
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 0 (M)
Shares Float 79 (M)
Held by Insiders 5.949e+007 (%)
Held by Institutions 24.6 (%)
Shares Short 794 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.415e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -5 %
Return on Assets (ttm) 237.5 %
Return on Equity (ttm) -106.5 %
Qtrly Rev. Growth 651040 %
Gross Profit (p.s.) 251.55
Sales Per Share 0
EBITDA (p.s.) 190304
Qtrly Earnings Growth -0.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -37.17
Stock Dividends
Dividend 0
Forward Dividend 704050
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android